Investor Presentation

Future Growth Avenues COVID-19-A Fundamental Tailwind • The COVID-19 pandemic has created a significant increase in demand for global demand for lung health technology In particular, the US has been one of the hardest-hit countries with ~7.5m confirmed cases and ~211k deaths, representing ~20% of the total deaths caused by COVID-19 globally* 4DMedical is currently working with leading US and Australians hospitals and clinics to potentially provide COVID-19 relevant assessment scans for the monitoring of the lungs using its XV Technology COVID-19 will substantially increase the demand for lung health assessments XV Technology clinical use cases • Emergency screening support (overflow) • • Improved patient triage: • As a diagnostic aid XV Technology provides lung function quantification to help determine initial treatment: home rest, admission to a ward or immediate admission to ICU As a surveillance tool: XV Technology provides faster feedback on treatment efficacy. This enables clinicians to make faster decisions in the type/level of patient care (alter treatment plan), and resourcing (e.g. move from ICU to ward) Accelerated therapy research . More sensitive than other tests / scans. Up to 6x faster feedback on changes in lung function Patient lung health monitoring post COVID-19 Reported Cases 0 to 1,000 5,001 to 10,000 1,001 to 5,000 10,001 to 20,000 40,001 or more AS GU MH FM MP PW PR VI Note: John Hopkins University & Medicine (as at 7 October 2020) Pg 32 Investor presentation 20,001 to 40,000 Image Source: National Centre for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases 4DMedical™ FORMERLY 4D

View entire presentation